CL2020002718A1 - Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos. - Google Patents

Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.

Info

Publication number
CL2020002718A1
CL2020002718A1 CL2020002718A CL2020002718A CL2020002718A1 CL 2020002718 A1 CL2020002718 A1 CL 2020002718A1 CL 2020002718 A CL2020002718 A CL 2020002718A CL 2020002718 A CL2020002718 A CL 2020002718A CL 2020002718 A1 CL2020002718 A1 CL 2020002718A1
Authority
CL
Chile
Prior art keywords
peptide
tyrosine
conjugates
glp
glucagon
Prior art date
Application number
CL2020002718A
Other languages
English (en)
Inventor
Ellen Chi
Rui Zhang
Suzanne Edavettal
Yue-Mei Zhang
Wilson Edwards
Raul Camacho
Martin A Case
Lisa Norquay
Mark J Wall
Songmao Zheng
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2020002718A1 publication Critical patent/CL2020002718A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención comprende conjugados que comprenden un péptido de fusión péptido similar al glucagón 1 (GLP-1) acoplado a un péptido PYY cíclico. La invención también se relaciona con composiciones farmacéuticas y con métodos para usarlas. Los conjugados novedosos son útiles para prevenir, tratar o corregir enfermedades y trastornos descritos en la presente descripción.
CL2020002718A 2018-04-25 2020-10-20 Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos. CL2020002718A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662313P 2018-04-25 2018-04-25
US2018029284 2018-04-25

Publications (1)

Publication Number Publication Date
CL2020002718A1 true CL2020002718A1 (es) 2021-01-29

Family

ID=66676857

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002718A CL2020002718A1 (es) 2018-04-25 2020-10-20 Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.

Country Status (26)

Country Link
EP (2) EP4640701A3 (es)
JP (2) JP7676148B2 (es)
KR (2) KR102865076B1 (es)
CN (2) CN112004822B (es)
AU (2) AU2019259790B2 (es)
BR (1) BR112020021562A2 (es)
CA (1) CA3096792A1 (es)
CL (1) CL2020002718A1 (es)
CO (1) CO2020013221A2 (es)
CR (1) CR20200487A (es)
DO (1) DOP2020000192A (es)
EC (1) ECSP20067968A (es)
ES (1) ES3049134T3 (es)
IL (2) IL319050A (es)
JO (1) JOP20200265A1 (es)
MA (1) MA52361A (es)
MX (2) MX2020011293A (es)
MY (1) MY207588A (es)
NI (1) NI202000071A (es)
PE (1) PE20211457A1 (es)
PH (1) PH12020551659A1 (es)
SA (1) SA520420401B1 (es)
SG (1) SG11202009844SA (es)
TW (1) TWI847981B (es)
UY (1) UY38200A (es)
WO (1) WO2019207505A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
CA3163507A1 (en) * 2019-12-04 2021-06-10 The Scripps Research Institute Peptide conjugates and methods of use
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
CN119638849A (zh) * 2021-10-18 2025-03-18 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
CN116478298A (zh) * 2021-12-31 2023-07-25 广东东阳光药业有限公司 Glp-1和gdf15的融合蛋白及其用途
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN117327200B (zh) * 2023-11-28 2024-02-09 西宝生物科技（上海）股份有限公司 一种调控糖脂代谢和抗衰老的双功能重组蛋白gik及其制备方法
WO2025247862A1 (en) * 2024-05-27 2025-12-04 Numaferm Gmbh Methods for the c-terminal modification of (poly)peptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094652A1 (en) * 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
EA011860B1 (ru) * 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
BRPI0518761A2 (pt) * 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
AU2006279276A1 (en) * 2005-07-29 2007-02-15 Amprotein Corporation Chimeric therapeutic agents
CN101296942A (zh) * 2005-08-11 2008-10-29 安米林药品公司 具有可选择特性的杂合多肽
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
SG10201406063XA (en) * 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
EP4442314A2 (en) * 2015-10-28 2024-10-09 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y

Also Published As

Publication number Publication date
KR102865076B1 (ko) 2025-09-25
PH12020551659A1 (en) 2021-07-26
CN119708256A (zh) 2025-03-28
IL278197B1 (en) 2025-03-01
JP2021522258A (ja) 2021-08-30
UY38200A (es) 2019-10-31
DOP2020000192A (es) 2021-04-30
EP3784692C0 (en) 2025-08-27
SA520420401B1 (ar) 2023-01-26
AU2023274117B2 (en) 2025-04-10
CR20200487A (es) 2021-03-11
PE20211457A1 (es) 2021-08-05
BR112020021562A2 (pt) 2021-03-02
JOP20200265A1 (ar) 2020-10-21
EP3784692A1 (en) 2021-03-03
IL278197B2 (en) 2025-07-01
JP7676148B2 (ja) 2025-05-14
AU2019259790B2 (en) 2023-08-31
AU2023274117A1 (en) 2023-12-21
CN112004822A (zh) 2020-11-27
ES3049134T3 (en) 2025-12-15
MA52361A (fr) 2021-03-03
IL278197A (en) 2020-11-30
TWI847981B (zh) 2024-07-11
MY207588A (en) 2025-03-05
AU2019259790A1 (en) 2020-10-22
EP4640701A3 (en) 2025-12-17
ECSP20067968A (es) 2020-11-30
CO2020013221A2 (es) 2020-11-10
JP2025118735A (ja) 2025-08-13
KR20210005674A (ko) 2021-01-14
CN112004822B (zh) 2025-01-14
MX2025014917A (es) 2026-02-03
EP4640701A2 (en) 2025-10-29
MX2020011293A (es) 2020-11-13
TW202014433A (zh) 2020-04-16
WO2019207505A1 (en) 2019-10-31
SG11202009844SA (en) 2020-11-27
EP3784692B1 (en) 2025-08-27
NI202000071A (es) 2021-01-21
KR20250142942A (ko) 2025-09-30
CA3096792A1 (en) 2019-10-31
IL319050A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
CO2020013221A2 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
BR112023003168A2 (pt) Compostos como agonistas do glp-1r
ECSP19029942A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
CO2017004489A2 (es) Polipéptidos fgf-21 modificados
UY37505A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
CR20230026A (es) Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532)
CY1123623T1 (el) Θεραπεια νευρολογικων νοσων
CY1126231T1 (el) Παραλλαγες ανθρωπινης αλφα-γαλακτοσιδασης
MX2020011007A (es) Derivado de péptido-1 (glp-1) similar al glucagón acilado.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
AR101871A1 (es) Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos
CL2021001209A1 (es) Constructos de suministro para transcitosis y métodos relacionados
MX9302475A (es) Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
CO2021011340A2 (es) Métodos de tratamiento profiláctico con vwf recombinante (rvwf)
EA202092547A1 (ru) Связанные со слитым пептидом, содержащим глюкагонподобный пептид 1 (glp-1), циклические пептидные тирозинтирозиновые конъюгаты и их применение
CO2021017960A2 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1
PE20190104A1 (es) Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos
MX2022006743A (es) Formulaciones liquidas estables de peptido 1 similar al glucagon o analogos del mismo.
JOP20250245A1 (ar) مركبات اندماجية واستخداماتها
AR117017A1 (es) Constructos de entrega para transcitosis y métodos relacionados